Recent News

• 08.04.2026 - ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities
• 07.23.2026 - ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center
• 07.15.2026 - ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
• 07.09.2026 - ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
• 06.09.2026 - ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
• 06.05.2026 - ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
• 06.03.2026 - ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
• 05.19.2026 - ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
• 05.12.2026 - ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
• 05.08.2026 - ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology

Recent Filings

• 07.24.2026 - DEF 14A Other definitive proxy statements
• 07.14.2026 - PRE 14A Other preliminary proxy statements
• 07.14.2026 - 8-K Current report
• 07.10.2026 - 8-K Current report
• 06.22.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.28.2026 - EFFECT Notice of Effectiveness
• 05.26.2026 - CORRESP Correspondence
• 05.26.2026 - UPLOAD SEC-generated letter